Iris Manor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2702050/publications.pdf Version: 2024-02-01



IDIS MANOD

#	Article	IF	CITATIONS
1	Polygenic association between attention-deficit/hyperactivity disorder liability and cognitive impairments. Psychological Medicine, 2022, 52, 3150-3158.	2.7	9
2	The Association between ADHD and the Severity of COVID-19 Infection. Journal of Attention Disorders, 2022, 26, 491-501.	1.5	27
3	The Association of Previous Vaccination with Live-Attenuated Varicella Zoster Vaccine and COVID-19 Positivity: An Israeli Population-Based Study. Vaccines, 2022, 10, 74.	2.1	5
4	Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study. International Journal of Environmental Research and Public Health, 2022, 19, 5993.	1.2	24
5	ADHD as a Risk Factor for Infection With Covid-19. Journal of Attention Disorders, 2021, 25, 1783-1790.	1.5	65
6	Possible Age-Related Progression of Attentional Impairment in ADHD and Its Attenuation by Past Diagnosis and Treatment. Journal of Attention Disorders, 2021, 25, 14-21.	1.5	6
7	The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test. Journal of Attention Disorders, 2021, 25, 1311-1320.	1.5	2
8	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	2.9	483
9	Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. Brain, Behavior, & Immunity - Health, 2021, 16, 100313.	1.3	9
10	The association of previous influenza vaccination and coronavirus disease-2019. Human Vaccines and Immunotherapeutics, 2021, 17, 2169-2175.	1.4	32
11	Continuous Performance Test Is Sensitive to a Single Methylphenidate Challenge in Preschool Children With ADHD. Journal of Attention Disorders, 2020, 24, 226-234.	1.5	3
12	Efficacy of Cognitive-Functional (Cog-Fun) Occupational Therapy Intervention Among Children With ADHD: An RCT. Journal of Attention Disorders, 2020, 24, 655-666.	1.5	19
13	Characterizing the Placebo Response in Adults With ADHD. Journal of Attention Disorders, 2020, 24, 425-433.	1.5	7
14	Editorial: Attention and Methylphenidate. Frontiers in Behavioral Neuroscience, 2020, 14, 66.	1.0	1
15	Contrasting effects of music on reading comprehension in preadolescents with and without ADHD. Psychiatry Research, 2020, 291, 113207.	1.7	12
16	Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 173-176.	0.7	13
17	Apparent lack of practice effects in the Test of Variables of Attention (TOVA) in adult ADHD. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 73-81.	1.7	8
18	High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder. International Clinical Psychopharmacology, 2019, 34, 138-142.	0.9	5

Iris Manor

#	Article	IF	CITATIONS
19	Attention-Deficit Hyperactivity Disorder in Pediatric Patients With Type 1 Diabetes Mellitus: Clinical Outcomes and Diabetes Control. Journal of Developmental and Behavioral Pediatrics, 2019, 40, 330-334.	0.6	21
20	Symptoms Versus Impairment in Adults With ADHD: Intercorrelations of the BRIEF-A, CAARS, and TOVA. Journal of Attention Disorders, 2019, 23, 1557-1566.	1.5	5
21	Cognitive-Functional (Cog-Fun) Dyadic Intervention for Children with ADHD and Their Parents: Impact on Parenting Self-Efficacy. Physical and Occupational Therapy in Pediatrics, 2018, 38, 444-456.	0.8	9
22	Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder. International Clinical Psychopharmacology, 2018, 33, 229-232.	0.9	6
23	Use of information and communication technologies among individuals with and without serious mental illness. Psychiatry Research, 2018, 266, 160-167.	1.7	21
24	Impact of the Cognitive–Functional (Cog–Fun) Intervention on Executive Functions and Participation Among Children With Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial. American Journal of Occupational Therapy, 2017, 71, 7105220010p1-7105220010p9.	0.1	22
25	Risk of Attention-Deficit/Hyperactivity Disorder in Children with Atopic Dermatitis. Acta Dermatovenerologica Croatica, 2017, 25, 210-214.	0.1	3
26	Familiality of Co-existing ADHD and Tic Disorders: Evidence from a Large Sibling Study. Frontiers in Psychology, 2016, 7, 1060.	1.1	5
27	New DSM-5 criteria for ADHD — Does it matter?. Comprehensive Psychiatry, 2016, 68, 56-59.	1.5	16
28	Attention-deficit/hyperactivity disorder in adults: update on clinical presentation and care. Neuropsychiatry, 2014, 4, 109-128.	0.4	20
29	Latent Inhibition in ADHD Adults On and Off Medication. Journal of Attention Disorders, 2014, 18, 625-631.	1.5	9
30	Efficacy of Metadoxine Extended Release in Patients With Predominantly Inattentive Subtype Attention-Deficit/Hyperactivity Disorder. Postgraduate Medicine, 2013, 125, 181-190.	0.9	12
31	Neuropsychological correlates of emotional lability in children with ADHD. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2012, 53, 1139-1148.	3.1	89
32	Are Names of Children with Attention Deficit Hyperactivity Disorder More â€~Hyperactive'?. Psychopathology, 2012, 45, 215-219.	1.1	2
33	Suicidal behavior and related traits among inpatient adolescents with first-episode schizophrenia. Comprehensive Psychiatry, 2011, 52, 596-599.	1.5	4
34	When Does It End? Attention-Deficit/Hyperactivity Disorder in the Middle Aged and Older Populations. Clinical Neuropharmacology, 2011, 34, 148-154.	0.2	41
35	Effectiveness and Safety of Citalopram in Hospitalized Adolescents With Major Depression. Clinical Neuropharmacology, 2011, 34, 182-185.	0.2	4
36	Effectiveness of Cognitive–Functional (Cog–Fun) Intervention With Children With Attention Deficit Hyperactivity Disorder: A Pilot Study. American Journal of Occupational Therapy, 2011, 65, 384-392.	0.1	44

Iris Manor

#	Article	IF	CITATIONS
37	Performance variability, impulsivity errors and the impact of incentives as genderâ€independent endophenotypes for ADHD. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2010, 51, 210-218.	3.1	127
38	Objective Versus Subjective Assessment of Methylphenidate Response. Child Psychiatry and Human Development, 2008, 39, 273-282.	1.1	15
39	Linkage to Chromosome 1p36 for Attention-Deficit/Hyperactivity Disorder Traits in School and Home Settings. Biological Psychiatry, 2008, 64, 571-576.	0.7	41
40	Confirmation That a Specific Haplotype of the Dopamine Transporter Gene Is Associated With Combined-Type ADHD. American Journal of Psychiatry, 2007, 164, 674-677.	4.0	125
41	Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects. Psychological Medicine, 2007, 37, 1703-1715.	2.7	151
42	Partial Replication of a DRD4 Association in ADHD Individuals Using a Statistically Derived Quantitative Trait for ADHD in a Family-Based Association Test. Biological Psychiatry, 2007, 62, 985-990.	0.7	28
43	ADHD, Temperament, and Parental Style as Predictors of the Child's Attachment Patterns. Child Psychiatry and Human Development, 2006, 37, 103-114.	1.1	68
44	Association of the dopamine D5 receptor with attention deficit hyperactivity disorder (ADHD) and scores on a continuous performance test (TOVA). American Journal of Medical Genetics Part A, 2004, 127B, 73-77.	2.4	50
45	Joint Analysis of the DRD5 Marker Concludes Association with Attention-Deficit/Hyperactivity Disorder Confined to the Predominantly Inattentive and Combined Subtypes. American Journal of Human Genetics, 2004, 74, 348-356.	2.6	168
46	High Serum Creatinine Kinase Level: Possible Risk Factor for Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology, 2002, 22, 252-256.	0.7	39
47	Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level. European Neuropsychopharmacology, 2001, 11, 111-115.	0.3	10
48	Organic disorders and psychosis. Current Opinion in Psychiatry, 1999, 12, 415-419.	3.1	1
49	Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis. Biological Psychiatry, 1998, 43, 288-292.	0.7	30
50	Neuroleptic malignant syndrome with gangliosidosis type II. Biological Psychiatry, 1997, 41, 1222-1224.	0.7	10